Background
Lung cancer is the leading cause of cancer mortality around the world [
1]. Although the advanced improvements have been made in the diagnosis and treatment, the 5-year survival rate of lung cancer patients is still far from satisfactory. One of the main reasons is that the metastasis emerges. Metastasis is a dynamic interaction between cancer cells and microenvironments. It was thought as a late event and only occurred when primary lesion had progressed locally. However, recent evidences suggested that metastasis also occurred in early-stage due to the spread of circulating tumor cells [
2,
3].
Although several pathways, including the Wnt/β-catenin pathway and the transforming growth factor-β (TGFβ) pathway, have been identified promoting the metastasis of cancer cells [
4], further scientific research is required to elaborate the process.
In order to analyze the lung cancer metastasis related components, we performed a screening assay and found that the dihydropyrimidinase Like 3 (DPYSL3) might contribute to the occurrence of metastasis in lung cancer.
DPYSL3, also named as CRMP4, is a member of cytosolic phosphoproteins family. It mediates the semaphorin/collapsin-induced growth cone collapse and regulates the neuronal differentiation [
5,
6]. The previous research about DPYSL3 mainly focused on development of nervous system as well as its related disease. Recently, different DPYSLs family members had been confirmed to be related with the metastasis of colon and prostate tumors [
7,
8]. Therefore it aroused our interest to ask what was the role of DPYSL3 in the metastasis of lung cancer. In this study, we observed the effect of DPYSL3 on cell motility, migration and invasion of lung cancer cells and analyzed the role of it in xenograft model. Furthermore, we confirmed that the increased TGFβ-induced epithelial-mesenchymal transition (EMT) caused by knockdown DPYSL3 might be responsible for metastasis of lung cancer.
Methods
Ethical approval
The protocol of this study was conducted according to the revised Declaration of Helsinki and approved by the Institutional Review Board (IRB) of Shanghai Pulmonary Hospital (Tongji University). Informed consent was obtained for experimentation with all participants. The privacy rights of participants were observed. All animal experiments were carried out in accordance with the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 8023, revised 1978).
Reagents and antibodies
Lipofectamine 2000 (Life Technologies), TGFβ (R&D Systems) and rabbit antibodies against TWIST (CST #46702), N-Cadherin (CST #4061) and GAPDH (CST #2118), were purchased from the indicated manufacturers. LLC cells were obtained from ATCC and cultured in DMEM supplemented with 10% FBS. To induce the EMT, the LLC cells were treated with 2 ng /mL TGFβ for 48 h.
Constructs
Mammalian expression plasmids for DPYSL3 were constructed following the recommendation of molecular cloning. The DPYSL3-RNAi target sequence were: #1, TACATGGAGGATGGCTTAATA; #2, CACCACCATGATCATTGACCA. The knockdown efficiency of DPYSL3-RNAi was determined at both mRNA and protein level.
Cell motility assay
Cell motility was assessed through scratch wound assay. Monolayer cells were seeded in six-well cell culture plates for 24 h. Then, the 200 μl pipette tip was used to introduce the wound with a width of 400–600 μm. Subsequently free-floating cells and debris were removed through PBS washing. The retained cells were cultured with serum-free medium. The wound healing was observed and photoed by the microscope 36 h later.
Stable DPYSL3 knockdown LLC cells
The lentiviral production was used to construct the stable cell lines.
The viral was produced with the HEK293 cells which were transfected with packaging plasmids together with the DPYSL3-RNAi plasmid. Twenty-four hours later, the medium was changed into DMEM medium without antibiotics and the cells were incubated for another 24 h. Then the LLC cells were transfected with the virus. They were cultured with the filtered recombinant virus-containing medium for 24 h and selected with puromycin (0.5 μg/ml). The control cells, which were stable GFPi knockdown LLC cells, were constructed with the same protocol. The knockdown efficiency was determined at both mRNA and protein level.
Cell migration and invasion assay
The 12-well transwell plates (8.0 μm pore filters) (Corning, NY) were used to determine the invasion and migration of LLC cells. For cell migration assay, the LLC cells (1 × 105) were seeded in the upper chamber of the transwell plate with serum-free DMEM medium. The DMEM medium with 10% FBS was added into the bottom chamber. The plate was incubated at 37 °C for 24 h. Then, the membrane of transwell was took off, fixed with 95% ethanol and stained with crystal violet staining. The cells got through the membrane were calculated under the microscope. For cell invasion assay, firstly, the membrane of 12-well transwell plate was coated with matrigel. Then the LLC cells were seeded in the upper chamber. The following protocol was the same with the migration assay.
Immunoblotting analysis
Cells were digested with 0.5% trypsinase and lysed with NP-40 lysis buffer on ice. Cancer tissues were put into homogenizer to grind into tissue homogenate with NP-40 lysis buffer. The concentration of each sample was determined through commercial kit. Then, the targeted molecules were fractionated through SDS/PAGE electrophoresis and subsequently transferred into the PVDF membrane. After blocking with 5% skimmed milk, the blot was incubated with the indicated antibody for 1 h. Following PBST washing, the blot was incubated with the appropriate secondary antibody. Then, it was developed with the ECL developing solution.
The 8-week-old male athymic immunodeficient Balb/c C57BL/6 mice were purchased from Shanghai laboratory animal center. The stable DPYSL3 or GFPi knockdown LLC (2 X 107) cells were injected via tail vein under strict aseptic operation. Lung tissues were harvested 6 weeks later and fixed in 4% PFA for histological characterization. The HE staining was performed according to the manufacturer’s instruction.
qPCR
Total RNA was isolated and purified from cancer tissues with Trizol (Invitrogen, Gaithersburg, MD, USA). It was transcripted into cDNA with the Invitrogen commercial kit. The details of RNA amplification method and subsequent enzymatic reaction have been previously reported [
9].
Total RNA was isolated for real-time PCR analysis to measure mRNA levels of the indicated genes. RNA was extracted (NIH purified usingedA was isolated for real-n,me PCR analysis to measure mRNA levels of the indicated genes. RNA was USA) following the manufacturer’s instructions. qRTPCR was performed on a Real-Time PCR system with SYBR Green qPCR Mix (Bio-rad, Hercules, CA, USA). For each gene, at least three separate sets of qRT-PCR analyses were performed. Data shown are the relative abundance of the indicated mRNA normalized to that of GAPDH.
Statistical analysis
All data were analyzed by the SPSS package for Windows (Version 18.0, Chicago, IL). t test was used to analyze the results of cell motility, proliferation, migration and invasion assay. The statistically significant refers to the P value < 0.05.
Discussion
Metastasis is a major cause of cancer related mortality of lung cancer. However, the mechanism underlying the progression of lung cancer metastasis is still poorly understood and the specific treatment target is still missing. The absolute damage caused by the distant metastasis in lung cancer exceeds that of local lesion. With the help of improved biological knowledge, several metastasis suppressors including kinases and GTP-binding proteins have been identified [
6,
10]. While the mechanism underlying their correlation is still unknown.
Our previous screening assay indicated that DPYSL3 might be a candidate metastatic lung cancer related molecule. The members of DPYSLs family were closely related to cancer progression and invasion. DPYSL1 was considered to be a lung cancer invasion suppressor gene [
11]. DPYSL2 had been identified as a colorectal carcinoma biomarker [
12]. It was also a negative regulator of p53 and had oncogenic activity [
13,
14].
DPYSL3, which is a cell-adhesion protein, has been reported to be involved in the metastasis of tumors [
4,
15‐
17]. But it played the opposite role in different cancers. In pancreatic cancer, inhibition of DPYSL3 reduced cellular invasion [
14,
18]. While in prostate cancer, overexpression of DPYSL3 decreased the cellular invasion and inhibited tumor metastasis [
4,
6,
15]. The correlation between DPYSL3 and lung cancer metastasis was still unknown. Therefore, in this study, we further analyzed the role of DPYSL3 in lung cancer metastasis. Our results suggested that DPYSL3 had influence on motility, migration and invasion of lung cancer cells. Furthermore, the occurrence of metastasis was inversely associated with the expression level of DPYSL3 in lung cancer patients. In order to elaborate the underlying molecular mechanisms of how DPYSL3 regulated the metastasis of lung cancer, we focused on the EMT changes and confirmed that knockdown DPYSL3 promoted TGFβ-induced EMT in LLC cells.
Acknowledgements
We appreciate the patients and their families for participating in this study.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (
http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (
http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.